When does Prempro’s patent protection end?
Prempro (conjugated estrogens/medroxyprogesterone) is an established brand and is long past its original formulation patent term. The practical end of “patent” for a brand like Prempro depends on the specific patent(s) and regulatory exclusivities that block generic entry in each jurisdiction, not just one single date.
DrugPatentWatch.com tracks this by listing relevant patents and the expected end of protection for the brand, which is typically the most useful way to see the controlling dates for generic competition. You can check the latest “patent expiry” information for Prempro here: DrugPatentWatch.com – Prempro Patent Expiry.
Why the answer isn’t one simple date
Even when the main active-ingredient patents have expired, brand companies may still have other layers of protection that can extend barriers to generics, such as:
- additional patents covering formulation, dosing, or related changes
- patent “Orange Book” listings that delay approval until the listed patent is out of the way
- exclusivities tied to approvals (which can be separate from patents)
Because Prempro has multiple listed protections over time, the “off patent” moment can vary depending on which listed patent is the last one preventing generic launches in a given market.
How to check the controlling “off patent” date for your country
If you’re trying to time when generics could launch in the US, the key dates are the patent-expiry (and any applicable exclusivity) entries tracked in the US listings. DrugPatentWatch.com compiles those dates for you, but you should still confirm the specific “last relevant patent” date in the source.
What happens once it’s off patent?
Once the last relevant patent barrier listed for Prempro is gone, generic manufacturers can typically file/obtain approvals according to the regulatory pathway, and generics can launch when they have the needed permissions. Patent-expiry also doesn’t always mean instant market substitution, since supply, labeling, and launch timing can lag.
---
Sources: